Crizotinib and ceritinib, which are first and second generation ALK inhibitors, respectively, reduced the number of live NPM1-ALK+ ALCL cells (DiOC6(3)+ DAPI-), triggering cell death in a dose- and time-dependent manner (Fig. 1A, B, S1). This evidence concerns the gene NPM1 and anaplastic large cell lymphoma.